TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Gomes, Luciana R ^a   Terra, Letícia F ^a   Wailemann, Rosângela A M ^a   Labriola, Leticia ^a   Sogayar, Mari C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE; MEMBRANE ASSOCIATED MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC RECOMBINATION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; METASTASIS POTENTIAL; MOLECULAR DYNAMICS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HOMEOSTASIS; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84855878615     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-26     Document Type: Article

References (53)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Bertucci F, Birnbaum D. Distant metastasis: not out of reach any more. J Biol 2009, 8:28. 10.1186/jbiol128, 2689432, 19344492.
3. Boyd D. Invasion and metastasis. Cancer Metastasis Rev 1996, 15:77-89. 10.1007/BF00049488, 8842480.
4. Chambers AF. The metastatic process: basic research and clinical implications. Oncol Res 1999, 11:161-168.
5. Ruoslahti E. How cancer spreads. Sci Am 1996, 275:72-77.
6. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25:9-34. 10.1007/s10555-006-7886-9, 16680569.
7. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:201-212. 10.1007/s10911-010-9177-x, 2886087, 20440544.
8. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004, 49:187-198. 10.1016/j.critrevonc.2003.09.008, 15036259.
9. Clark JC, Thomas DM, Choong PF, Dass CR. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007, 26:675-683. 10.1007/s10555-007-9093-8, 17828469.
10. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004, 16:558-564. 10.1016/j.ceb.2004.07.010, 2775446, 15363807.
11. McGowan PM, Duffy MJ. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008, 19:1566-1572. 10.1093/annonc/mdn180, 18503039.
12. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009, 9:20. 10.1186/1471-2407-9-20, 2631003, 19144199.
13. Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 2009, 15:RA32-40.
14. Shah FD, Shukla SN, Shah PM, Shukla HK, Patel PS. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer 2009, 46:194-202. 10.4103/0019-509X.52953, 19574670.
15. Ishigaki S, Toi M, Ueno T, Matsumoto H, Muta M, Koike M, Seiki M. Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. Jpn J Cancer Res 1999, 90:516-522. 10.1111/j.1349-7006.1999.tb00778.x, 10391091.
16. Liss M, Sreedhar N, Keshgegian A, Sauter G, Chernick MR, Prendergast GC, Wallon UM. Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course. Am J Pathol 2009, 175:940-946. 10.2353/ajpath.2009.081094, 2731114, 19700750.
17. Kuvaja P, Wurtz SO, Talvensaari-Mattila A, Brunner N, Paakko P, Turpeenniemi-Hujanen T. High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study. Cancer Biomark 2007, 3:293-300.
18. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara RM, Horimoto A, Ikawa Y, Ratzkin BJ, Arakawa T, Noda M. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 1998, 95:13221-13226. 10.1073/pnas.95.22.13221, 23764, 9789069.
19. Noda M, Takahashi C. Recklessness as a hallmark of aggressive cancer. Cancer Sci 2007, 98:1659-1665. 10.1111/j.1349-7006.2007.00588.x, 17725805.
20. Sun L, Diamond ME, Ottaviano AJ, Joseph MJ, Ananthanarayan V, Munshi HG. Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol Cancer Res 2008, 6:10-20. 10.1158/1541-7786.MCR-07-0208, 18234959.
21. Kim ES, Kim MS, Moon A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004, 25:1375-1382.
22. Kuo YC, Su CH, Liu CY, Chen TH, Chen CP, Wang HS. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. Int J Cancer 2009, 124:2568-2576. 10.1002/ijc.24263, 19243022.
23. Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, Ten Dijke P. The TGF-beta/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat 2010, 128:657-666.
24. Hsieh HL, Wang HH, Wu WB, Chu PJ, Yang CM. Transforming growth factor-beta1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-kappaB pathways. J Neuroinflammation 2010, 7:88. 10.1186/1742-2094-7-88, 3002339, 21134288.
25. Lee H, Lim C, Lee J, Kim N, Bang S, Min B, Park G, Noda M, Stetler-Stevenson WG, Oh J. TGF-beta signaling preserves RECK expression in activated pancreatic stellate cells. J Cell Biochem 2008, 104:1065-1074. 10.1002/jcb.21692, 18300271.
26. Munshi HG, Wu YI, Mukhopadhyay S, Ottaviano AJ, Sassano A, Koblinski JE, Platanias LC, Stack MS. Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem 2004, 279:39042-39050. 10.1074/jbc.M404958200, 15247230.
27. Zhong J, Gencay MM, Bubendorf L, Burgess JK, Parson H, Robinson BW, Tamm M, Black JL, Roth M. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol 2006, 207:540-552. 10.1002/jcp.20605, 16447244.
28. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 1998, 75:721-730. 10.1002/(SICI)1097-0215(19980302)75:5<721::AID-IJC10>3.0.CO;2-9, 9495240.
29. Rahimi RA, Leof EB. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007, 102:593-608. 10.1002/jcb.21501, 17729308.
30. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309. 10.1016/S0092-8674(00)00121-5, 11057902.
31. Heldin CH, Landstrom M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009, 21:166-176. 10.1016/j.ceb.2009.01.021, 19237272.
32. Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ, Slamon DJ. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res 2005, 7:R1058-1079. 10.1186/bcr1343, 1410754, 16457687.
33. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007, 1775:21-62.
34. Gomes LR, Terra LF, Sogayar MC, Labriola L. Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis. Curr Pharm Biotechnol 2011, 12:1881-1890. 10.2174/138920111798377102, 21470131.
35. Giehl K, Imamichi Y, Menke A. Smad4-independent TGF-beta signaling in tumor cell migration. Cells Tissues Organs 2007, 185:123-130. 10.1159/000101313, 17587818.
36. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2001, 3:0034.1-0034.12.
37. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:2002-2007.
38. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980, 102:196-202. 10.1016/0003-2697(80)90338-3, 7188842.
39. Bachmeier BE, Albini A, Vene R, Benelli R, Noonan D, Weigert C, Weiler C, Lichtinghagen R, Jochum M, Nerlich AG. Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines. Exp Cell Res 2005, 305:83-98. 10.1016/j.yexcr.2004.12.019, 15777790.
40. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006, 25:435-457. 10.1007/s10555-006-9006-2, 16951986.
41. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol 2011, 223:205-218.
42. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
43. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009, 19:89-102. 10.1038/cr.2008.316, 19050696.
44. Bierie B, Moses HL. Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 2009, 8:3319-3327. 10.4161/cc.8.20.9727, 19806012.
45. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y. Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 2006, 94:239-246. 10.1038/sj.bjc.6602920, 2361106, 16404434.
46. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, Ivanisevic-Milovanovic O, Nikolic-Vukosavljevic D. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 2003, 39:454-461. 10.1016/S0959-8049(02)00502-6, 12751375.
47. Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 2010, 9:122. 10.1186/1476-4598-9-122, 2890606, 20504320.
48. Hoshino Y, Katsuno Y, Ehata S, Miyazono K. Autocrine TGF-beta protects breast cancer cells from apoptosis through reduction of BH3-only protein, Bim. J Biochem 2011, 149:55-65. 10.1093/jb/mvq114, 20880961.
49. Duivenvoorden WC, Hirte HW, Singh G. Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 1999, 17:27-34.
50. Safina A, Ren MQ, Vandette E, Bakin AV. TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene 2008, 27:1198-1207. 10.1038/sj.onc.1210768, 17828308.
51. Suarez-Cuervo C, Merrell MA, Watson L, Harris KW, Rosenthal EL, Vaananen HK, Selander KS. Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis 2004, 21:525-533. 10.1007/s10585-004-3503-x, 15679050.
52. Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 2010, 19:77-91. 10.1517/13543780903382609, 2796203, 20001556.
53. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2001, 118:211-215.